Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lidocaine and Dexmedetomidine for Postoperative Sore Throat in Thyroid Cancer Surgery
NCT06952309Not yet recruiting
- Sponsor
- Anqing Municipal Hospital
- Start
- Apr 2025
- Primary completion
- Sep 2025
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial of Lidocaine Hydrochloride Injection, without epinephrine and dexmedetomidine in postoperative sore throat (POST) (4 arms), sponsored by Anqing Municipal Hospital. Primary endpoint: The incidence and severity of postoperative sore throat at 48 hours. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
Lidocaine Hydrochloride Injection, without epinephrinedexmedetomidine
03
Conditions
postoperative sore throat (POST)
Beyond the preview
Go deeper on NCT06952309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06952309.